Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cross Country Healthcare Announces Third Quarter 2024 Financial Results

CCRN

Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its third quarter ended September 30, 2024.

SELECTED FINANCIAL INFORMATION:

Variance

Variance

Q3 2024 vs

Q3 2024 vs

Dollars are in thousands, except per share amounts

Q3 2024

Q3 2023

Q2 2024

Revenue

$

315,119

(29

)%

(7

)%

Gross profit margin*

20.4

%

(160

)bps

(40

)bps

Net income attributable to common stockholders

$

2,555

(80

)%

116

%

Diluted EPS

$

0.08

$

(0.28

)

$

0.55

Adjusted EBITDA*

$

10,339

(62

)%

(27

)%

Adjusted EBITDA margin*

3.3

%

(290

)bps

(90

)bps

Adjusted EPS*

$

0.12

$

(0.27

)

$

0.02

Cash flows provided by operations

$

7,470

(89

)%

(91

)%

* Represents amounts that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP) and are referred to as non-GAAP measures. Please refer to the accompanying discussion below of how these non-GAAP financial measures are calculated and used under “Non-GAAP Financial Measures” and the tables reconciling these measures to the closest GAAP measure.

Third Quarter Business Highlights

  • Revenue, Adjusted EBITDA, and Adjusted EPS all within guidance ranges
  • Physician Staffing and Homecare Staffing experienced sequential and year-over-year revenue growth
  • Secured a three-year contract renewal with our largest managed service program
  • Continued strong balance sheet with $64 million of cash on hand and no debt as of September 30, 2024
  • Repurchased over 800,000 shares of common stock for $11.9 million

“Our third quarter results reflect the continued stabilization across our core business as well as the ongoing momentum in our Homecare, Physician, and Education Staffing businesses. Though margins remain under pressure, I am encouraged to see demand for our services continue to rise amidst bill rate stability,” said John A. Martins, President and Chief Executive Officer of Cross Country Healthcare. He continued, “We find ourselves well positioned to capitalize on the market as it normalizes, by leveraging our strong balance sheet to make strategic investments, that we believe will deliver long-term profitability."

Third quarter consolidated revenue was $315.1 million, a decrease of 29% year-over-year and 7% sequentially. Consolidated gross profit margin was 20.4%, down 160 basis points year-over-year and 40 basis points sequentially. Net income attributable to common stockholders was $2.6 million, as compared to $12.8 million in the prior year and a net loss of $16.1 million in the prior quarter. Diluted income per share (EPS) was $0.08, as compared to $0.36 in the prior year and a net loss of $0.47 in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $10.3 million, or 3.3% of revenue, as compared with $27.2 million, or 6.2% of revenue, in the prior year, and $14.2 million, or 4.2% of revenue, in the prior quarter. Adjusted EPS was $0.12, as compared to $0.39 in the prior year and $0.10 in the prior quarter.

For the nine months ended September 30, 2024, consolidated revenue was $1,034.1 million, a decrease of 36% year-over-year. Consolidated gross profit margin was 20.5%, down 190 basis points year-over-year. Net loss attributable to common stockholders was $10.8 million, or $0.32 per diluted share, as compared to net income of $63.6 million, or $1.78 per diluted share, in the prior year. Adjusted EBITDA was $39.8 million, or 3.8% of revenue, as compared to $123.8 million, or 7.7% of revenue, in the prior year. Adjusted EPS was $0.41, as compared to $1.92 in the prior year.

Quarterly Business Segment Highlights

Nurse and Allied Staffing

Revenue was $264.9 million, a decrease of 33% year-over-year and 9% sequentially. Contribution income was $19.3 million, a decrease from $39.2 million year-over-year and an increase from $5.8 million sequentially. The sequential increase was primarily the result of $19.4 million of credit loss expense driven by a bankruptcy filing by a single large customer recognized during the second quarter of 2024. Average field contract personnel on a full-time equivalent (FTE) basis was 7,660, as compared with 9,849 in the prior year and 8,415 in the prior quarter. Revenue per FTE per day was $373, as compared to $434 in the prior year and $377 in the prior quarter.

Physician Staffing

Revenue was $50.3 million, an increase of 10% year-over-year and 4% sequentially. Contribution income was $4.6 million, an increase from $2.6 million year-over-year and $4.0 million sequentially. Total days filled were 24,424, as compared with 23,004 in the prior year and 24,252 in the prior quarter. Revenue per day filled was $2,058, as compared with $1,986 in the prior year and $1,992 in the prior quarter.

Cash Flow and Balance Sheet Highlights

Net cash provided by operating activities for the three months ended September 30, 2024 was $7.5 million, as compared to $70.3 million for the three months ended September 30, 2023 and $82.4 million for the three months ended June 30, 2024. We experienced a 4 day year-over-year improvement in days' sales outstanding. For the nine months ended September 30, 2024, net cash provided by operating activities was $95.9 million, as compared to $236.4 million in the prior year.

During the third quarter, the Company repurchased over 800,000 shares of the Company’s common stock for an aggregate price of $11.9 million, at an average market price of $14.57 per share. As of September 30, 2024, the Company had 32.6 million unrestricted shares outstanding and $44.1 million remaining for share repurchase.

As of September 30, 2024, the Company had $64.0 million in cash and cash equivalents with no debt outstanding. There were no borrowings drawn under its revolving senior secured asset-based credit facility (ABL). As of September 30, 2024, borrowing base availability under the ABL was $150.2 million, with $135.2 million of availability net of $15.0 million of letters of credit.

Outlook for Fourth Quarter 2024

The guidance below applies to management’s expectations for the fourth quarter of 2024.

Q4 2024 Range

Year-over-Year

Sequential

Change

Change

Revenue

$300 million - $310 million

(28%)% - (25%)%

(5%)% - (2%)%

Adjusted EBITDA*

$11.0 million - $13.0 million

(47%)% - (37%)%

6%% - 26%

Adjusted EPS*

$0.10 - $0.14

$(0.19) - $(0.15)

$(0.02) - $0.02

* Refer to discussion of non-GAAP financial measures and the reconciliation tables below.

The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases.

INVITATION TO CONFERENCE CALL

The Company will hold its quarterly conference call on Wednesday, November 6, 2024, at 5:00 P.M. Eastern Time to discuss its third quarter 2024 financial results. This call will be webcast live and can be accessed at the Company’s website at ir.crosscountry.com or by dialing 888-566-1290 from anywhere in the U.S. or by dialing 773-799-3776 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from November 6th through November 20th on the Company’s website and a replay of the conference call will be available by telephone by calling 800-835-4610 from anywhere in the U.S. or 203-369-3352 from non-U.S. locations - Passcode: 4915.

ABOUT CROSS COUNTRY HEALTHCARE

Cross Country Healthcare, Inc. is a market-leading, tech-enabled workforce solutions and advisory firm with 38 years of industry experience and insight. We help clients tackle complex labor-related challenges and achieve high-quality outcomes, while reducing complexity and improving visibility through data-driven insights. Diversity, equality, and inclusion is at the heart of the organization’s overall corporate social responsibility program, and closely aligned with our core values to create a better future for its people, communities, and its stockholders.

Copies of this and other press releases, as well as additional information about the Company, can be accessed online at ir.crosscountry.com. Stockholders and prospective investors can also register to automatically receive the Company’s press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

NON-GAAP FINANCIAL MEASURES

This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes such non-GAAP financial measures are useful to investors when evaluating the Company’s performance, as such non-GAAP financial measures exclude certain items that management believes are not indicative of the Company’s future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

In addition, forward-looking adjusted EBITDA and adjusted EPS for fiscal 2024 exclude potential charges or gains that may be recorded during the fiscal year, including among other things, the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases. We have not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of our financial performance.

FORWARD-LOOKING STATEMENTS

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995, and are subject to the safe harbor created by those sections. Forward-looking statements consist of statements that are predictive in nature and/or depend upon or refer to future events. Words such as expects,anticipates,intends,plans,believes,estimates,suggests,appears,seeks,will,could, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the overall macroeconomic environment, including increased inflation and interest rates, demand for the healthcare services that we provide, both nationally and in the regions in which we operate, our ability to attract and retain qualified nurses, physicians, and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, including data privacy and protection laws, social, ethical, and security issues relating to the use of artificial intelligence, our customers ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors, including, without limitation, the risk factors set forth in Item 1A. Risk Factors in the Companys Annual Report on Form 10-K for the year ended December 31, 2023, as filed and updated in our Quarterly Reports on Form 10-Q and other filings with the SEC. You should consult any further disclosures that the Company makes on related subjects in its filings with the SEC.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect managements opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. Except as may be required by law, the Company undertakes no obligation to update or revise forward-looking statements. All references to the Company,we,us,our, or Cross Country in this press release mean Cross Country Healthcare, Inc. and its consolidated subsidiaries.

Cross Country Healthcare, Inc.

Consolidated Statements of Operations

(Unaudited, amounts in thousands, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

June 30,

September 30,

September 30,

2024

2023

2024

2024

2023

Revenue from services

$

315,119

$

442,291

$

339,771

$

1,034,064

$

1,605,693

Operating expenses:

Direct operating expenses

250,961

344,932

268,966

821,804

1,245,772

Selling, general and administrative expenses

54,297

69,627

60,258

177,807

232,825

Credit loss expense

1,512

2,355

18,858

21,660

10,397

Depreciation and amortization

4,498

4,540

4,719

13,859

13,876

Restructuring costs

998

348

2,116

4,052

1,690

Legal and other losses

3,946

7,596

1,125

Impairment charges

186

114

718

719

Total operating expenses

312,266

421,988

358,977

1,047,496

1,506,404

Income (loss) from operations

2,853

20,303

(19,206

)

(13,432

)

99,289

Other expenses (income):

Interest expense

550

669

568

1,580

7,508

Loss on early extinguishment of debt

1,723

Interest income

(1,107

)

(5

)

(235

)

(1,515

)

(12

)

Other expense (income) , net

21

139

23

(1,013

)

145

Income (loss) before income taxes

3,389

19,500

(19,562

)

(12,484

)

89,925

Income tax expense (benefit)

834

6,688

(3,512

)

(1,681

)

26,332

Net income (loss) attributable to common stockholders

$

2,555

$

12,812

$

(16,050

)

$

(10,803

)

$

63,593

Net income (loss) per share attributable to common stockholders - Basic

$

0.08

$

0.37

$

(0.47

)

$

(0.32

)

$

1.80

Net income (loss) per share attributable to common stockholders - Diluted

$

0.08

$

0.36

$

(0.47

)

$

(0.32

)

$

1.78

Weighted average common shares outstanding:

Basic

33,016

34,954

33,960

33,728

35,386

Diluted

33,058

35,152

33,960

33,728

35,742

Cross Country Healthcare, Inc.

Reconciliation of Non-GAAP Financial Measures

(Unaudited, amounts in thousands, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

June 30,

September 30,

September 30,

2024

2023

2024

2024

2023

Adjusted EBITDA:a

Net income (loss) attributable to common stockholders

$

2,555

$

12,812

$

(16,050

)

$

(10,803

)

$

63,593

Interest expense

550

669

568

1,580

7,508

Income tax expense (benefit)b

834

6,688

(3,512

)

(1,681

)

26,332

Depreciation and amortization

4,498

4,540

4,719

13,859

13,876

Acquisition and integration-related costs

13

59

Restructuring costsc

998

348

2,116

4,052

1,690

Legal, bankruptcy, and other lossesd

23,319

26,969

1,125

Impairment chargese

186

114

718

719

Loss on disposal of fixed assets

43

43

Loss on early extinguishment of debtf

1,723

Loss on lease termination

96

104

Interest income

(1,107

)

(5

)

(235

)

(1,515

)

(12

)

Other expense (income), net

21

23

(1,013

)

(2

)

Equity compensation

870

1,433

2,259

4,327

5,413

System conversion costsg

1,120

425

857

3,306

1,658

Adjusted EBITDAa

$

10,339

$

27,248

$

14,178

$

39,799

$

123,829

Adjusted EBITDA margina

3.3

%

6.2

%

4.2

%

3.8

%

7.7

%

Adjusted EPS:h

Numerator:

Net income (loss) attributable to common stockholders

$

2,555

$

12,812

$

(16,050

)

$

(10,803

)

$

63,593

Non-GAAP adjustments - pretax:

Acquisition and integration-related costs

13

59

Restructuring costsc

998

348

2,116

4,052

1,690

Legal, bankruptcy, and other lossesd

23,319

26,969

1,125

Impairment chargese

186

114

718

719

Other income, net

(1,115

)

Loss on early extinguishment of debtf

1,723

System conversion costsg

1,120

425

857

3,306

1,658

Tax impact of non-GAAP adjustments

(552

)

(208

)

(7,066

)

(9,023

)

(1,767

)

Adjusted net income attributable to common stockholders - non-GAAP

$

4,121

$

13,576

$

3,290

$

14,104

$

68,800

Denominator:

Weighted average common shares - basic, GAAP

33,016

34,954

33,960

33,728

35,386

Dilutive impact of share-based payments

42

198

42

155

356

Adjusted weighted average common shares - diluted, non-GAAP

33,058

35,152

34,002

33,883

35,742

Reconciliation:

Diluted EPS, GAAP

$

0.08

$

0.36

$

(0.47

)

$

(0.32

)

$

1.78

Non-GAAP adjustments - pretax:

Restructuring costsc

0.03

0.01

0.06

0.12

0.05

Legal, bankruptcy, and other lossesd

0.69

0.79

0.03

Impairment chargese

0.01

0.02

0.02

Other income, net

(0.03

)

Loss on early extinguishment of debtf

0.05

System conversion costsg

0.03

0.01

0.03

0.10

0.04

Tax impact of non-GAAP adjustments

(0.02

)

(0.21

)

(0.27

)

(0.05

)

Adjusted EPS, non-GAAPh

$

0.12

$

0.39

$

0.10

$

0.41

$

1.92

Cross Country Healthcare, Inc.

Consolidated Balance Sheets

(Unaudited, amounts in thousands)

September 30,

December 31,

2024

2023

Assets

Current assets:

Cash and cash equivalents

$

64,021

$

17,094

Accounts receivable, net

244,987

372,352

Income taxes receivablei

10,128

8,620

Prepaid expenses

4,554

7,681

Insurance recovery receivable

12,102

9,097

Other current assets

794

2,031

Total current assets

336,586

416,875

Property and equipment, net

28,975

27,339

Operating lease right-of-use assets

2,700

2,599

Goodwill

135,430

135,430

Other intangible assets, net

46,453

54,468

Deferred tax assetsi

9,038

5,979

Insurance recovery receivable

21,812

25,714

Cloud computing

9,735

5,987

Other assets

6,694

6,673

Total assets

$

597,423

$

681,064

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable and accrued expensesi

$

58,436

$

92,822

Accrued compensation and benefits

54,285

52,297

Operating lease liabilities

2,060

2,604

Earnout liability

4,100

6,794

Other current liabilities

1,796

1,559

Total current liabilities

120,677

156,076

Operating lease liabilities

2,348

2,663

Accrued claims

34,893

34,853

Earnout liability

5,000

Uncertain tax positions

11,169

10,603

Other liabilities

3,645

4,218

Total liabilities

172,732

213,413

Commitments and contingencies

Stockholders’ equity:

Common stock

3

4

Additional paid-in capital

204,273

236,417

Accumulated other comprehensive loss

(1,397

)

(1,385

)

Retained earningsi

221,812

232,615

Total stockholders’ equity

424,691

467,651

Total liabilities and stockholders’ equity

$

597,423

$

681,064

Cross Country Healthcare, Inc.

Segment Dataj

(Unaudited, amounts in thousands)

Three Months Ended

Year-over-
Year

Sequential

September 30,

% of

September 30,

% of

June 30,

% of

% change

% change

2024

Total

2023

Total

2024

Total

Fav (Unfav)

Fav (Unfav)

Revenue from services:

Nurse and Allied Staffing

$

264,853

84

%

$

396,595

90

%

$

291,451

86

%

(33

)%

(9

)%

Physician Staffing

50,266

16

%

45,696

10

%

48,320

14

%

10

%

4

%

$

315,119

100

%

$

442,291

100

%

$

339,771

100

%

(29

)%

(7

)%

Contribution income:k

Nurse and Allied Staffing

$

19,251

$

39,226

$

5,820

(51

)%

231

%

Physician Staffing

4,629

2,576

4,033

80

%

15

%

23,880

41,802

9,853

(43

)%

142

%

Corporate overheadl

15,531

16,412

18,161

5

%

14

%

Depreciation and amortization

4,498

4,540

4,719

1

%

5

%

Restructuring costsc

998

348

2,116

(187

)%

53

%

Legal and other lossesm

3,946

%

100

%

Impairment chargese

186

114

100

%

100

%

Other costs

13

3

100

%

100

%

Income (loss) from operations

$

2,853

$

20,303

$

(19,206

)

(86

)%

115

%

Nine Months Ended

Year-over-
Year

September 30,

% of

September 30,

% of

% change

2024

Total

2023

Total

Fav (Unfav)

Revenue from services:

Nurse and Allied Staffing

$

888,490

86

%

$

1,474,273

92

%

(40

)%

Physician Staffing

145,574

14

%

131,420

8

%

11

%

$

1,034,064

100

%

$

1,605,693

100

%

(36

)%

Contribution income:k

Nurse and Allied Staffing

$

52,254

$

162,876

(68

)%

Physician Staffing

11,800

7,841

50

%

64,054

170,717

(62

)%

Corporate overheadl

51,258

53,959

5

%

Depreciation and amortization

13,859

13,876

%

Restructuring costsc

4,052

1,690

(140

)%

Legal and other lossesm

7,596

1,125

(575

)%

Impairment chargese

718

719

%

Other costs

3

59

95

%

(Loss) income from operations

$

(13,432

)

$

99,289

(114

)%

Other costs include acquisition and integration-related costs.

Cross Country Healthcare, Inc.

Summary Condensed Consolidated Statements of Cash Flows

(Unaudited, amounts in thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

June 30,

September 30,

September 30,

2024

2023

2024

2024

2023

Net cash provided by operating activities

$

7,470

$

70,311

$

82,401

$

95,882

$

236,424

Net cash used in investing activities

(1,124

)

(3,408

)

(2,849

)

(6,183

)

(10,900

)

Net cash used in financing activities

(11,926

)

(53,273

)

(15,193

)

(42,772

)

(214,825

)

Effect of exchange rate changes on cash

(2

)

(2

)

Change in cash and cash equivalents

(5,580

)

13,628

64,359

46,927

10,697

Cash and cash equivalents at beginning of period

69,601

673

5,242

17,094

3,604

Cash and cash equivalents at end of period

$

64,021

14,301

$

69,601

$

64,021

$

14,301

Cross Country Healthcare, Inc.

Other Financial Data

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

June 30,

September 30,

September 30,

2024

2023

2024

2024

2023

Revenue from services

$

315,119

$

442,291

$

339,771

$

1,034,064

$

1,605,693

Less: Direct operating expenses

250,961

344,932

268,966

821,804

1,245,772

Gross profit

$

64,158

$

97,359

$

70,805

$

212,260

$

359,921

Consolidated gross profit marginn

20.4

%

22.0

%

20.8

%

20.5

%

22.4

%

Nurse and Allied Staffing statistical data:

FTEso

7,660

9,849

8,415

8,400

11,251

Average Nurse and Allied Staffing revenue per FTE per dayp

$

373

$

434

$

377

$

383

$

476

Physician Staffing statistical data:

Days filledq

24,424

23,004

24,252

72,461

68,927

Revenue per day filledr

$

2,058

$

1,986

$

1,992

$

2,009

$

1,907

(a)

Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on lease termination, gain or loss on sale of business, other expense (income), net, equity compensation, and system conversion costs. Adjusted EBITDA is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income (loss) attributable to common stockholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.

(b)

The decrease in income tax expense for the three and nine months ended September 30, 2024 related to a decrease in book income primarily driven by credit loss expense.

(c)

Restructuring costs were primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives.

(d)

Includes legal costs and other settlement charges as presented on the consolidated statements of operations, losses pertaining to matters outside the normal course of operations, and $19.4 million of credit loss expense driven by a bankruptcy filing by a single large customer for the nine months ending September 30, 2024. There was no significant impact on operations from this client as the majority of the business had been wound down in the prior year. For the nine months ended September 30, 2023, the Company incurred $1.1 million, including legal fees, to settle a wage and hour class action lawsuit.

(e)

Impairment charges for the nine months ended September 30, 2024 were related to right-of-use assets and related property in connection with vacated leases during 2024. Impairment charges for the nine months ended September 30, 2023 primarily related to the write-off of an abandoned IT project.

(f)

Loss on early extinguishment of debt for the nine months ended September 30, 2023 consisted of the write-off of debt issuance costs related to the payoff and termination of the term loan on June 30, 3023.

(g)

System conversion costs include enterprise resource planning system costs related to the upgrading and integrating of our middle and back-office platforms, with certain development costs capitalized and amortized in accordance with the Company’s policies, and applicant tracking system costs related to the Company’s project to replace its legacy system supporting its travel nurse staffing business.

(h)

Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, system conversion costs, and nonrecurring income tax adjustments. Adjusted EPS is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes Adjusted EPS provides a more useful comparison of the Company’s underlying business performance from period to period and is more representative of the future earnings capacity of the Company than EPS. Quarterly non-GAAP adjustment may vary due to rounding.

(i)

Financial information included in the December 31, 2023 balance sheet includes immaterial revisions to the Company's previously-reported financial information. Please see the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the SEC, for more information.

(j)

Segment data is provided in accordance with the Segment Reporting Topic of the Financial Accounting Standards Board Accounting Standards Codification.

(k)

Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.

(l)

Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and Company-wide projects (initiatives).

(m)

Legal and other losses includes legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations.

(n)

Gross profit is defined as revenue from services less direct operating expenses. The Company’s gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.

(o)

FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.

(p)

Average revenue per FTE per day is calculated by dividing Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.

(q)

Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours.

(r)

Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today